1. Home
  2. SPRY
  3. SPRY News

Latest ARS Pharmaceuticals Inc. (SPRY) News on May 22, 2025

What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today
SPRY

Simply Wall St.

7 days ago

What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today

SPRY

GuruFocus.com

8 days ago

ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ...

SPRY

Thomson Reuters StreetEvents

8 days ago

Q1 2025 ARS Pharmaceuticals Inc Earnings Call

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
SPRY

Zacks

8 days ago

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates

SPRY

MT Newswires

8 days ago

ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
SPRY

GlobeNewswire

8 days ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect
SPRY

GuruFocus.com

9 days ago

ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect

ARS Pharma’s epinephrine nasal spray 1mg now available in US
SPRY

Pharmaceutical Technology

14 days ago

ARS Pharma’s epinephrine nasal spray 1mg now available in US

ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
SPRY

GlobeNewswire

15 days ago

ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals And 2 Other Growth Leaders With Insider Ownership
SPRY

Simply Wall St.

16 days ago

ARS Pharmaceuticals And 2 Other Growth Leaders With Insider Ownership

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
SPRY

GlobeNewswire

17 days ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

SPRY

MT Newswires

20 days ago

ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
SPRY

GlobeNewswire

20 days ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

US High Growth Tech Stocks To Watch Now
SPRY

Simply Wall St.

a month ago

US High Growth Tech Stocks To Watch Now

ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money
SPRY

Insider Monkey

2 months ago

ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money

High Insider Ownership Growth Stocks To Know In April 2025
SPRY

Simply Wall St.

2 months ago

High Insider Ownership Growth Stocks To Know In April 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year
SPRY

Simply Wall St.

2 months ago

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year

Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz
SPRY

TipRanks

2 months ago

Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz

ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect
SPRY

GuruFocus.com

2 months ago

ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect

ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
SPRY

Simply Wall St.

2 months ago

ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

SPRY

GuruFocus.com

2 months ago

ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...

SPRY

Thomson Reuters StreetEvents

2 months ago

Q4 2024 ARS Pharmaceuticals Inc Earnings Call

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
SPRY

Investor's Business Daily

2 months ago

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.

SPRY

MT Newswires

2 months ago

Sector Update: Health Care Stocks Decline Pre-Bell Thursday

SPRY

MT Newswires

2 months ago

Sector Update: Health Care

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates
SPRY

Zacks

2 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates

SPRY

MT Newswires

2 months ago

ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
SPRY

GlobeNewswire

2 months ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Exploring High Growth Tech Stocks in the US Market
SPRY

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks in the US Market

FDA approves ARS’ neffy 1mg for paediatric anaphylaxis
SPRY

Pharmaceutical Technology

3 months ago

FDA approves ARS’ neffy 1mg for paediatric anaphylaxis

SPRY

MT Newswires

3 months ago

ARS Pharmaceuticals Says US FDA Approves Lower Dosage of Neffy Nasal Spray

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
SPRY

GlobeNewswire

3 months ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

3 Growth Companies With High Insider Ownership Growing Earnings Up To 61%
SPRY

Simply Wall St.

3 months ago

3 Growth Companies With High Insider Ownership Growing Earnings Up To 61%

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
SPRY

GlobeNewswire

3 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
SPRY

GlobeNewswire

3 months ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

SPRY

MT Newswires

3 months ago

VR Resources Completes Drilling at Silverback Copper-Gold Project in Northwest Ontario

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
SPRY

GlobeNewswire

3 months ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

SPRY

MT Newswires

3 months ago

Oppenheimer Initiates ARS Pharmaceuticals at Outperform

SPRY

MT Newswires

4 months ago

VR Resources Provides Exploration Update on Silverback and Empire Projects in Ontario

ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
SPRY

GlobeNewswire

4 months ago

ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

3 US Growth Stocks With Significant Insider Ownership
SPRY

Simply Wall St.

4 months ago

3 US Growth Stocks With Significant Insider Ownership

SPRY

MT Newswires

4 months ago

VR Resources Says Drilling Underway At Silverback Copper-Gold Project

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
SPRY

GlobeNewswire

4 months ago

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
SPRY

Investor's Business Daily

4 months ago

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Exploring Three High Growth Tech Stocks In The United States
SPRY

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks In The United States

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
SPRY

GlobeNewswire

4 months ago

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals files for approval of neffy in Canada, U.K.
SPRY

TipRanks

4 months ago

ARS Pharmaceuticals files for approval of neffy in Canada, U.K.

ARS Pharma seeks approval for epinephrine spray in Canada and UK
SPRY

Medical Device Network

4 months ago

ARS Pharma seeks approval for epinephrine spray in Canada and UK

SPRY

MT Newswires

5 months ago

ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
SPRY

GlobeNewswire

5 months ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Top US Growth Companies With Insider Ownership In January 2025
SPRY

Simply Wall St.

5 months ago

Top US Growth Companies With Insider Ownership In January 2025

Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green
SPRY

Simply Wall St.

5 months ago

Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
SPRY

GlobeNewswire

5 months ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SPRY

GlobeNewswire

5 months ago

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SPRY

MT Newswires

5 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $1,768,093, According to a Recent SEC Filing

SPRY

MT Newswires

5 months ago

ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
SPRY

GlobeNewswire

5 months ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

SPRY

MT Newswires

5 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $2,041,200, According to a Recent SEC Filing

SPRY

MT Newswires

6 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $2,688,751, According to a Recent SEC Filing

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
SPRY

GlobeNewswire

6 months ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

US Growth Stocks With High Insider Ownership For November 2024
SPRY

Simply Wall St.

6 months ago

US Growth Stocks With High Insider Ownership For November 2024

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term
SPRY

Simply Wall St.

6 months ago

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term

SPRY

MT Newswires

6 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $10,143,706, According to a Recent SEC Filing

SPRY

GuruFocus.com

6 months ago

ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
SPRY

Zacks

6 months ago

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates

SPRY

MT Newswires

6 months ago

ARS Pharmaceuticals' Q3 Net Loss Widens

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
SPRY

GlobeNewswire

6 months ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy
SPRY

TipRanks

6 months ago

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
SPRY

Investor's Business Daily

6 months ago

ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray

ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
SPRY

Pharmaceutical Technology

6 months ago

ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

SPRY

MT Newswires

6 months ago

ARS Pharmaceuticals Licenses Neffy Nasal Spray to ALK-Abello for Europe, Canada

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
SPRY

Benzinga

6 months ago

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
SPRY

GlobeNewswire

6 months ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet
SPRY

Zacks

7 months ago

Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
SPRY

GlobeNewswire

7 months ago

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

SPRY

MT Newswires

7 months ago

VR Resources Confirms Gold in Porphyry Intrusion Cutting Nickel Sulfide Mineralization at Silverback Project in Ontario

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
SPRY

GlobeNewswire

7 months ago

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
SPRY

Simply Wall St.

7 months ago

Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade
SPRY

Zacks

7 months ago

Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade

Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?
SPRY

Pharmaceutical Technology

8 months ago

Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?

SPRY

MT Newswires

8 months ago

ARS Pharmaceuticals Launches Neffy Nasal Spray in US

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
SPRY

GlobeNewswire

8 months ago

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals (SPRY): A Bull Case Theory
SPRY

Insider Monkey

8 months ago

ARS Pharmaceuticals (SPRY): A Bull Case Theory

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
SPRY

GlobeNewswire

8 months ago

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

SPRY

MT Newswires

8 months ago

ARS Pharmaceuticals Submits Supplemental NDA for Needle-Free Neffy Dose for Children

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
SPRY

GlobeNewswire

8 months ago

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

Insider Returns Down To US$660k As ARS Pharmaceuticals' Stock Dips 12%
SPRY

Simply Wall St.

8 months ago

Insider Returns Down To US$660k As ARS Pharmaceuticals' Stock Dips 12%

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why
SPRY

Zacks

9 months ago

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
SPRY

GlobeNewswire

9 months ago

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

SPRY

MT Newswires

9 months ago

ARS Pharmaceuticals Says EC Approves EURneffy for Emergency Treatment of Allergic Reactions

EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
SPRY

GlobeNewswire

9 months ago

EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

SPRY

MT Newswires

9 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $11,497,963, According to a Recent SEC Filing

Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
SPRY

Benzinga

9 months ago

Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned

SPRY

MT Newswires

9 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $1,502,587, According to a Recent SEC Filing

ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares
SPRY

GuruFocus.com

9 months ago

ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares

ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
SPRY

Benzinga

9 months ago

ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst

Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY)
SPRY

GuruFocus.com

9 months ago

Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY)

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval
SPRY

Pharmaceutical Technology

9 months ago

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

SPRY

MT Newswires

9 months ago

ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions

FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
SPRY

Benzinga

9 months ago

FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment

Share on Social Networks: